| Literature DB >> 31952147 |
Silvia Voci1, Agnese Gagliardi1,2, Massimo Fresta1, Donato Cosco1.
Abstract
The introduction of nanotechnology into pharmaceutical application revolutionized the administration of antitumor drugs through the modulation of their accumulation in specific organs/body compartments, a decrease in their side-effects and their controlled release from innovative systems. The use of plant-derived proteins as innovative, safe and renewable raw materials to be used for the development of polymeric nanoparticles unlocked a new scenario in the drug delivery field. In particular, the reduced size of the colloidal systems combined with the peculiar properties of non-immunogenic polymers favored the characterization and evaluation of the pharmacological activity of the novel nanoformulations. The aim of this review is to describe the physico-chemical properties of nanoparticles composed of vegetal proteins used to retain and deliver anticancer drugs, together with the most important preparation methods and the pharmacological features of these potential nanomedicines.Entities:
Keywords: antitumor compounds; gliadin; legumin; nanoparticles; soy protein isolate; zein
Year: 2020 PMID: 31952147 PMCID: PMC7023308 DOI: 10.3390/pharmaceutics12010065
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321
Figure 1Main advantages and disadvantages of using plant proteins in drug delivery.
Figure 2Schematic representation of the architecture of solid tumor vessels. Reproduced with permission from [59]. Copyright (2018) Elsevier.
Figure 3(A) SEM micrograph of sodium-deoxycholate stabilized zein nanoparticles (bar = 100 nm) and (B) in vitro antitumor activity of paclitaxel (PTX)-loaded nanosystems on various human cancer cell lines. * p < 0.05, ** p < 0.001 (with respect to the untreated cells). Adapted with permission from [91], copyright (2018) DOVE Medical Press and [113] copyright (2019) Elsevier.
Figure 4Release profile of cyclophosphamide from gliadin- or gliadin/gelatin-based nanoparticles as a function of the incubation time (* p < 0.05). Reproduced with permission from [142]; copyright (2012) ACS Publications.
Composition, physico-chemical characteristics and antitumor application of vegetal protein-based nanoparticles.
| Protein | Encapsulated Drug | Method of Fabrication | Mean Sizes (nm) | PDI | Type of Treated Cancer Cells/Application | Reference | |
|---|---|---|---|---|---|---|---|
| Zein | Daidzin | Modified Antisolvent Precipitation | 150–200 | 0.2–0.3 | 20 | / | [ |
| 6,7-dyhydroxicoumarin | pH controlled nanoprecipitation | 300–400 | 0.36 | −11 ± 18 | / | [ | |
| Doxorubicin | Phase Separation | 200–250 | 0.15–0.20 | ~−50 | HeLa cells | [ | |
| 5-Fluorouracil | Phase Separation | 100–150 | / | −46 ± 1 | Liver targeting | [ | |
| Paclitaxel | Nanoprecipitation | <200 | 0.2 | ~−30 | MCF-7; K562 | [ | |
| Curcumin | Antisolvent precipitation | 109 | 0.12 | ~−30 | Caco-2 | [ | |
| Exemestane and Resveratrol | Interfacial deposition | 127 ± 3 | 0.13 | ~−32 | Breast Cancer | [ | |
| Vorinostat and Bortezomib | Phase Separation | 150 | 0.20 | −20/−30 | Metastatic prostate cancer | [ | |
| Gliadin | All- | Desolvation | ~500 | / | −4 | / | [ |
| Paclitaxel | Desolvation and Film Hydration | 160 ± 20 | 0.18 | −21 ± 3 | MCF-7; MDA-MB-231 | [ | |
| Cyclophosphamide | Electrospray deposition | ~220 | / | ~18 | Breast cancer cells | [ | |
| Curcumin | Desolvation | ~200 | 0.4 | ~−20 | Colon cancer | [ | |
| Legumin | Methylene Blue | pH coacervation | 250–300 | / | ~−40 | / | [ |
| Soy | Curcumin | Desolvation | 220–286 | / | ~−35 | / | [ |
| Soy-Folate | Curcumin | Desolvation | 170–300 | / | −36 | Caco 2 | [ |
| Soy-folate | Doxorubicin | Desolvation | 232 | / | −28, pH 5; | 293 T, MCF-7, SH-SY5Y cells | [ |
| Soy | Doxorubicin | Desolvation | 206 | / | −20, pH 5; | 293 T, MCF-7, SH-SY5Y | [ |
| Soy | Docetaxel | Antisolvent precipitation-ultrasonication | ~250 | 0.3–0.4 | ~−10/−15 | / | [ |